Benchling Announces Collaboration with Merck on Vaccine Bioanalysis
Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment
"Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis," said
"Sophisticated data management capabilities are integral to advancing vaccine research and development," said
About Benchling
Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling R&D Cloud as their central source of truth for scientific data, analysis, and collaboration. With software purpose-built for biology, Benchling is on a mission to unlock the power of biotechnology. To learn more, visit Benchling.com.
View original content:https://www.prnewswire.com/news-releases/benchling-announces-collaboration-with-merck-on-vaccine-bioanalysis-302478378.html
SOURCE Benchling
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Telit Cinterion and Commstar Radio Partner to Bring Multi-Network Connectivity to Municipal and Critical Infrastructure Operations
- ETF Architect Announces Name Change of the Towle Value ETF to the Towle Small-Cap Value ETF
- Lightstone DIRECT Surpasses $225 Million in Total Investment Volume Less Than a Year After Launch
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share